MOORESTOWN, N.J., Sept. 11, 2017 -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, today announced that an unprecedented 100% of its eligible clinicians within subsidiary CareKinesis, have achieved Board Certified Geriatric Pharmacist (BCGP) recognition. The certification distinguishes pharmacists for their in-depth knowledge of geriatric drug therapy and as preferred providers of care for seniors.
|
|||
Today’s older adults have unique medication management needs as they manage multiple diseases and medications at the same time. However, traditional training of health professionals focuses on basic physiology, diseases, and use of medication to treat a particular disease, according to the Commission for Certification in Geriatric Pharmacy (CCGP), the national program for accredited certification of BCGPs. As a result, most prescribers and pharmacists tend to focus on the treatment of one disease or the use of one drug at a time. BCGPs are trained to look at the whole patient, evaluate all the diseases he/she is being treated for and evaluate the current medication regiment for its overall safety and effectiveness, potentially avoiding unnecessary hospital admissions and adverse drug events (ADEs).
“TRHC’s geriatric-certified pharmacists know that the focus must be on the total patient, looking at all relevant intrinsic and extrinsic factors to evaluate appropriateness of drug therapy,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “Medication safety remains our highest priority, for our people and through the technologies we provide to the market. This is an unprecedented achievement for our subsidiary company, CareKinesis, which achieved the 100% certification.”
Pharmacists who meet CCGP’s criteria and pass the examination are entitled to use the designation “Board Certified Geriatric Pharmacist” and place the initials BCGP after their name.
“When I need it, I want a Board Certified Geriatric Pharmacist on my own healthcare team,” said Robert L. Alesiani, PharmD, BCGP and Chief Pharmacotherapy Officer for CareKinesis. “I believe BCGPs are more likely to help decrease medication-related risk, reduce adverse drug events and enhance compliance, adherence and quality of life.”
“Thanks to Dr. Alesiani’s leadership and example, 100% of our eligible staff have taken and passed this rigorous exam,” said Dr. Knowlton. “We congratulate our pharmacists and thank them for the tremendous service they provide in assuring the best possible personalized medication therapy care.”
About Tabula Rasa HealthCare, Inc.
Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Since 2011, TRHC, through its wholly-owned subsidiary, CareKinesis, has focused on optimizing outcomes for PACE and other healthcare organizations using its unique Medication Risk Mitigation software and Medication Decision Support and Adherence tools that personalize each participants medication regimen. For more information, please visit: www.TRHC.com.
Contact:
TRHC
Dianne Semingson
[email protected]
T: 215-870-0829


Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
First Western Ship Transits Strait of Hormuz Since Iran War Began
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Apple Turns 50: From Garage Startup to AI Crossroads
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 



